StageZero Life Sciences Ltd T.SZLS

Zero confidence in this CEO

[LittleGuy2]

Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set - Annals of Oncology

Glass half full...
at least this Grail sponsored study may bring attention to the cancer detection space.

Glass half empty...
Tripp's leadersip has squandered a 2 year jump on Grail because he couldn't set up a study with a group of physician-scientists that would give the medical community some evidence they could follow complete with world-wide media attention.  

If you can't download the article just check the Guardian or the CBC, or any other news outlet on the planet.

[Jonnyboy85]

My God will you guys give it up already? Grail is 50% accurate, a coin toss, if you have it or don't. "Overall sensitivity for cancer signal detection was 51.5% (49.6% to 53.3%)"

[LittleGuy2]

With all respect, you're missing the point...even with superior sensitivity & specificity, we, (speaking as a long), are being vastly outpaced by an inferior product.  Promote the tech, just get new leadership.  The new acquisition is not a group of research physicians, just a bunch of clinicians taking the opportunity to add a new frill to bill.

[Jonnyboy85]

The only thing grail has is oodles of investors money to blow on pr, our product speaks for itself. The medical community and cancer community can't and won't take 50% guesses at cancer because that's what we're already doing, stagezero knows that and they're playing to win long term with a product that doesn't leave room for doubt. Grails short term press blitzing is

[LithLover]

Bang on.  And if you are technical I would recommend reading up on cfDNA technology versus our mRNA technology. There is a reason that the covid vaccines were created so quickly using mRNA technology and so much talk around mRNA    

[LithLover]

And grail is still a year or more away.  From the grail article : Researchers will continue to collect data from the test in large studies across the U.S. The company has also partnered with the U.K.’s National Health Service to pilot the test in approximately 165,000 eligible patients, starting later this year.  

[davewho]

not sure I agree witrh your statement. The new acquisition is not a group of research physicians, just a bunch of clinicians taking the opportunity to add a new frill to bill. The Care Oncology team seems well staffed with research scientists.  Care Oncology - About Us - Consultants and Leadership Team